1.Jain, MK, Ridker, PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews Drug Discovery 2005; 4: 977–987.
2.Baigent, C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
3.Fedson, DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clinical Infectious Diseases 2006; 43: 199–205.
4.Alegret, M, Silvestre, JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods & Findings in Experimental & Clinical Pharmacology 2006; 28: 627–656.
5.Blanco-Colio, LM, et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney International 2003; 63: 12–23.
6.Novack, V, Terblanche, M, Almog, Y. Do statins have a role in preventing or treating sepsis? Critical Care 2006; 10: 113.
7.Schonbeck, U, Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109 (21 Suppl. 1): II18–II26.
8.Colhoun, HM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.
9.Collins, R, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–767.
10.Almog, Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003; 124: 740–743.
11.Almog, Y, et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Critical Care Medicine 2007; 35: 372–378.
12.Almog, Y, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880–885.
13.Liappis, AP, et al. The effect of statins on mortality in patients with bacteremia. Clinical Infectious Diseases 2001; 33: 1352–1357.
14.Cheung, CY, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360: 1831–1837.
15.Frost, FJ, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006–1012.
16.Majumdar, SR, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. British Medical Journal 2006; 333: 999.
17.Mortensen, EM, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respiratory Research 2005; 6: 82.
18.Schlienger, RG, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27: 325–332.
19.van de Garde, EM, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61: 957–961.
20.Smeeth, L, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology 2009; 67: 99–109.
21.Fleming, DM. Weekly Returns Service of the Royal College of General Practitioners. Communicable Disease and Public Health 1999; 2: 96–100.
22.Chisholm, J. The Read clinical classification. British Medical Journal 1990; 300: 1092.
23.Fleming, DM, Elliot, AJ. Lessons from 40 years' surveillance of influenza in England and Wales. Epidemiology and Infection 2008; 136: 866–875.
24.StataCorp. Intercooled Stata version 10. College Station, TX, USA: Stata Corporation, 2007.
25.Fleming, DM, et al. Respiratory illness associated with influenza and respiratory syncytial virus infection. Archives of Diseases in Childhood 2005; 90: 741–746.
26.Hall, SA, et al. The relationship of common medical conditions and medication use with symptoms of painful bladder syndrome: results from the Boston area community health survey. Journal of Urology 2008; 180: 593–598.
27.Packard, RR, et al. Atorvastatin treatment and vaccination efficacy. Journal of Clinical Pharmacology 2007; 47: 1022–1027.
28.Hak, E, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clinical Infectious Diseases 2002; 35: 370–377.
29.Jackson, LA, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology 2006; 35: 337–344.
30.Simonsen, L, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infectious Diseases 2007; 7: 658–666.
31.Greenland, S, Lash, TL. Bias analysis. In: Rothman, KJ, Greenland, S, Lash, TL, eds. Modern Epidemiology, 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008, pp. 345–380.
32.Fleming, DM, Cross, KW, Pannell, RS. Influenza and its relationship to circulatory disorders. Epidemiology and Infection 2005; 133: 255–262.
33.Nichol, KL, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New England Journal of Medicine 2003; 348: 1322–1332.
34.Verel, D, Ward, C, Rickards, DF. Proceedings: Electrocardiographic changes in A2 England-42–72 influenza infection in patients treated at home. British Heart Journal 1974; 36: 395.
35.Verel, D, et al. Observations on the A2 England influenza epidemic: a clinicopathological study. American Heart Journal 1976; 92: 290–296.
36.Ridker, PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008; 359: 2195–2207.